OncoMatch/Clinical Trials/NCT06926543
Postoperative Radiotherapy in Breast Cancer- Concurrent or Sequential With Chemotherapy
Is NCT06926543 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Chemoradiation and Chemoradiation for invasive breast cancer.
Treatment: Chemoradiation · Chemoradiation — This clinical research aims to determine if concurrent chemotherapy and radiation therapy is more effective than sequential chemotherapy and radiation therapy for patients with stage IIB-III breast cancer. It seeks to answer the following key questions: 1. When compared to sequential treatment, does concurrent chemoradiotherapy increase disease-free survival? 2. What effects does concurrent treatment have on post-operative look, quality of life, and side effects including arm swelling (lymphoedema)? 3. What are each treatment approach's financial costs? Researchers will compare the following to groups: Arm A: Participants in the sequential treatment group will first undergo chemotherapy and then radiation. and Arm B: Participants in the concurrent treatment group will undergo radiation therapy while undergoing chemotherapy. Participants are going to: 1. Get the usual chemotherapy (taxanes and/or anthracyclines). 2. Receive radiation therapy for three to four weeks. 3. Have follow-up visits every 6months for 5years to check for cancer recurrence, side effects, and quality of life.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Required: Stage IIB, III
Prior therapy
Cannot have received: neoadjuvant chemotherapy
Patients receiving entire chemotherapy prior to surgery (neoadjuvant setting)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify